Corbus Pharmaceuticals Holding Stock Performance
| CRBP Stock | USD 38.77 0.05 0.13% |
On a scale of 0 to 100, Corbus Pharmaceuticals holds a performance score of 11. The firm shows a Beta (market volatility) of -0.66, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Corbus Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Corbus Pharmaceuticals is likely to outperform the market. Please check Corbus Pharmaceuticals' expected short fall, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether Corbus Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Corbus Pharmaceuticals Holding are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Even with relatively fragile fundamental drivers, Corbus Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.13 | Five Day Return 1.92 | Year To Date Return 513.27 | Ten Year Return (56.87) | All Time Return (56.87) |
Last Split Factor 1:30 | Last Split Date 2023-02-14 |
1 | Acquisition by Sean Moran of 40176 shares of Corbus Pharmaceuticals subject to Rule 16b-3 | 02/14/2024 |
2 | Insider Trading | 02/27/2024 |
3 | Acquisition by Smethurst Dominic of 50000 shares of Corbus Pharmaceuticals at 26.07 subject to Rule 16b-3 | 02/29/2024 |
4 | Acquisition by Cormorant Asset Management, Lp of 46799 shares of Corbus Pharmaceuticals at 37.82 subject to Rule 16b-3 | 03/07/2024 |
5 | Corbus Pharmaceuticals Q4 Earnings Snapshot | 03/12/2024 |
6 | Corbus Pharmaceuticals files for 300M mixed shelf offering | 03/13/2024 |
7 | What Makes Corbus Pharmaceuticals a Good Fit for Trend Investing | 03/15/2024 |
8 | Disposition of 53610 shares by Sean Moran of Corbus Pharmaceuticals at 1.0 subject to Rule 16b-3 | 03/22/2024 |
9 | Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC | 04/02/2024 |
10 | Disposition of 1787 shares by Sean Moran of Corbus Pharmaceuticals at 30.0 subject to Rule 16b-3 | 04/10/2024 |
11 | Heres What Could Help Corbus Pharmaceuticals Maintain Its Recent Price Strength | 04/16/2024 |
12 | Marijuana Stock Movers For April 25, 2024 | 04/25/2024 |
13 | Acquisition by Avery Catlin of 79600 shares of Corbus Pharmaceuticals subject to Rule 16b-3 | 04/26/2024 |
14 | Corbus Pharmaceuticals in Focus Stock Moves 6 percent Higher - Yahoo Lifestyle Australia | 05/03/2024 |
| Begin Period Cash Flow | 17.2 M |
Corbus |
Corbus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 2,402 in Corbus Pharmaceuticals Holding on February 7, 2024 and sell it today you would earn a total of 1,475 from holding Corbus Pharmaceuticals Holding or generate 61.41% return on investment over 90 days. Corbus Pharmaceuticals Holding is currently generating 0.993% in daily expected returns and assumes 6.7399% risk (volatility on return distribution) over the 90 days horizon. In different words, 59% of stocks are less volatile than Corbus, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Corbus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corbus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Corbus Pharmaceuticals Holding, and traders can use it to determine the average amount a Corbus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1473
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CRBP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.74 actual daily | 59 59% of assets are less volatile |
Expected Return
| 0.99 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Corbus Pharmaceuticals is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Corbus Pharmaceuticals by adding it to a well-diversified portfolio.
Corbus Pharmaceuticals Fundamentals Growth
Corbus Stock prices reflect investors' perceptions of the future prospects and financial health of Corbus Pharmaceuticals, and Corbus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Corbus Stock performance.
| Return On Equity | -3.42 | ||||
| Return On Asset | -0.6 | ||||
| Current Valuation | 406.8 M | ||||
| Shares Outstanding | 10.51 M | ||||
| Price To Earning | (8.87) X | ||||
| Price To Book | 1,491 X | ||||
| Price To Sales | 163.32 X | ||||
| Gross Profit | (16.14 M) | ||||
| EBITDA | (44.44 M) | ||||
| Net Income | (44.6 M) | ||||
| Cash And Equivalents | 66.23 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 20.88 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 3.86 X | ||||
| Book Value Per Share | (1.56) X | ||||
| Cash Flow From Operations | (36.1 M) | ||||
| Earnings Per Share | (10.31) X | ||||
| Market Capitalization | 407.36 M | ||||
| Total Asset | 28.27 M | ||||
| Retained Earnings | (436.68 M) | ||||
| Working Capital | (8.35 M) | ||||
| Current Asset | 12.71 M | ||||
| Current Liabilities | 3.63 M | ||||
About Corbus Pharmaceuticals Performance
To evaluate Corbus Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Corbus Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Corbus Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Corbus Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Corbus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.2 K | 1.2 K | |
| Return On Tangible Assets | (1.58) | (1.66) | |
| Return On Capital Employed | 12.45 | 13.07 | |
| Return On Assets | (1.58) | (1.66) | |
| Return On Equity | 6.46 | 6.78 |
Things to note about Corbus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Corbus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Corbus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Corbus Pharmaceuticals is way too risky over 90 days horizon | |
| Corbus Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Corbus Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (44.6 M) with loss before overhead, payroll, taxes, and interest of (16.14 M). | |
| Corbus Pharmaceuticals Holding currently holds about 66.23 M in cash with (36.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Corbus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Corbus Pharmaceuticals in Focus Stock Moves 6 percent Higher - Yahoo Lifestyle Australia |
- Analyzing Corbus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Corbus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Corbus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Corbus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Corbus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Corbus Pharmaceuticals' stock. These opinions can provide insight into Corbus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Complementary Tools for Corbus Stock analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.60) | Return On Equity (3.42) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.